At Boehringer Ingelheim our purpose is simply to ‘Make More Health’ - for patients, our people and our community. We are a family-owned, independent company and operate in over 50 countries with more than 47,000 employees.
For over a century we have practiced excellence, innovation and value in the discovery of medicines and services and have remained committed to operating as an ethical and sustainable company. We are constantly seeking new and better ways to treat diseases.
Working in close collaboration with the international scientific community and a number of the world’s leading cancer centres, Boehringer Ingelheim’s commitment to oncology is underpinned applying its scientific discoveries and research advances in cancer biology to develop a wide range of novel therapies in areas of unmet medical need in both solid tumours and haematological malignancies. Boehringer Ingelheim’s oncology pipeline is evolving and demonstrates the company’s continued commitment to advance the disease area.